Annual Report and Accounts
for the year ended 31 December 2021
We protect lives from invisible threats by providing actionable health information in the right place, at the right time.
Global leaders in the fight against infectious diseases
Novacyt is a diagnostics solution provider, manufacturing diagnostic and pathogen testing kits based on molecular and protein technologies sold into human clinical, life science, food and industrial markets.
As soon as we started to see that there was a need for COVID-19 testing, we thought of Novacyt immediately. We wanted to collaborate as soon as we can as we have a long working relationship.
Novacyt were very good; they had one of the first recognised products on the market which is the genesig® COVID-19 1G. First validation with the assay was good, and we didn’t see any problem. It is a nice assay that you can run a variety of different ways and it works on open platforms.”
Tony Cooke, CEO @ Cambridge Clinical Labs
Build a sustainable base business across in vitro diagnostics in human health, life sciences research portfolio serving veterinary, food, water and human health with integrated instrumentation to enable semi-automated, scalable, near patient testing
Maximise COVID portfolio internationally “NOW”
Develop innovative future “non-COVID menu” for underserved market segments
Prioritise key markets & define go-to market strategies
Develop integrated instrument strategy
Leverage life sciences legacy business
Build e-commerce capability
The innovation engine enabling “global first response”
Our base business with breadth and depth of portfolio acts as the innovation engine to enable Novacyt to respond rapidly to disease outbreaks and to also serve neglected diseases. With enhanced surveillance mechanism and our agility, Novacyt continues to be a global first responder
Global surveillance capability
Latent resource capacity
Install “COBRA-like” internal response team
Address customer complexity
Agile resource deployment
Appoint global scientific expert panel
Rapid development and launch of 15 new assays to support laboratories, clinicians, and private testing of COVID-19 since the beginning of 2021
Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing
Inclusion in National Framework Agreement, resulting in a new £4.7m contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS
Secured new contracts with WHO and UNICEF for the supply of COVID-19 products
Growth of new markets for private testing, including travel, sport, film, media, and workplace settings
Rapid development and launch of 15 new assays to support laboratories, clinicians, and private testing of COVID-19 since the beginning of 2021
Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing
Inclusion in National Framework Agreement, resulting in a new £4.7m contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS
Secured new contracts with WHO and UNICEF for the supply of COVID-19 products
Growth of new markets for private testing, including travel, sport, film, media, and workplace settings